GRAL
GRAIL, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.82
P/S
14.42
EV/EBITDA
-5.31
DCF Value
$-19.24
FCF Yield
-14.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-42.5%
Operating Margin
-382.0%
Net Margin
-277.5%
ROE
-17.1%
ROA
-14.0%
ROIC
-15.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $43.6M | $-99.2M | $-2.44 |
| FY 2025 | $147.2M | $-408.4M | $-11.11 |
| Q3 2025 | $36.2M | $-89.0M | $-2.46 |
| Q2 2025 | $35.5M | $-114.0M | $-3.18 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
5.21
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.